Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection

Heart and Vessels

Volumn 20, Issue 4, 2005, Pages 171-174

  Spieker, Lukas E ^a   Karadag, Bilgehan ^a   Binggeli, Christian ^a   Corti, Roberto ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiretroviral therapy; Atherosclerosis; Coronary artery disease; Human immunodeficiency virus

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; EZETIMIBE; LISINOPRIL; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RAPAMYCIN; STAVUDINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE REPORT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DRUG ELUTING STENT; DRUG POTENTIATION; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; RISK ASSESSMENT;

ADULT; ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS;

EID: 22744432409     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-004-0790-8     Document Type: Article

References (28)

1. MR Chester L Chen JC Kaski 1996 The natural history of unheralded complex coronary plaques J Am Coll Cardiol 28 604-608
2. W Casscells K Hassan MF Vaseghi MS Siadaty M Naghavi RL Kirkeeide MR Hassan M Madjid 2003 Plaque blush, branch location, and calcification are angiographic predictors of progression of mild to moderate coronary stenoses Am Heart J 145 813-820
3. S Jost JW Deckers P Nikutta W Rafflenbeul B Wiese H Hecker P Lippolt PR Lichtlen 1993 Progression of coronary artery disease is dependent on anatomic location and diameter. The INTACT investigators J Am Coll Cardiol 21 1339-1346
4. S Jost JW Deckers P Nikutta B Wiese W Rafflenbeul H Hecker P Lippolt PR Lichtlen 1994 Evolution of coronary stenoses is related to baseline severity - a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy Eur Heart J 15 648-653
5. K Kure YD Part TS Kim WD Lyman G Lantos S Lee S Cho AL Belman KM Weidenheim DW Dickson 1989 Immunohistochemical localization of an HIV epitope in cerebral aneurysmal arteriopathy in pediatric acquired immunodeficiency syndrome (AIDS) Pediatr Pathol 9 655-667
6. R Chetty 2001 Vasculitides associated with HIV infection J Clin Pathol 54 275-278
7. R Nair JV Robbs NG Naidoo J Woolgar 2000 Clinical profile of HIV-related aneurysms Eur J Vasc Endovasc Surg 20 235-240
8. S Aoun E Ramos 2000 Hypertension in the HIV-infected patient Curr Hypertens Rep 2 478-481
9. D Periard A Telenti P Sudre JJ Cheseaux P Halfon MJ Reymond SM Marcovina MP Glauser P Nicod R Darioli V Mooser 1999 Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study Circulation 100 700-705
10. JH Stein MA Klein JL Bellehumeur PE McBride DA Wiebe JD Otvos JM Sosman 2001 Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Circulation 104 257-262
11. A Carr K Samaras S Burton M Law J Freund DJ Chisholm DA Cooper 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 F51-58
12. GM Behrens AR Boerner K Weber J van den Hoff J Ockenga G Brabant RE Schmidt 2002 Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy J Clin Invest 110 1319-1327
13. A Carr K Samaras A Thorisdottir GR Kaufmann DJ Chisholm DA Cooper 1999 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study Lancet 353 2093-2099
14. J Dressman J Kincer SV Matveev L Guo RN Greenberg T Guerin D Meade XA Li W Zhu A Uittenbogaard ME Wilson EJ Smart 2003 HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages J Clin Invest 111 389-397
15. M Mary-Krause L Cotte A Simon M Partisani D Costagliola 2003 Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men AIDS 17 2479-2486
16. SD Holmberg AC Moorman JM Williamson TC Tong DJ Ward KC Wood AE Greenberg RS Janssen the HIV Outpatient Study (HOPS) investigators 2002 Protease inhibitors and cardiovascular outcomes in patients with HIV-1 Lancet 360 1747-1748
17. SA Bozzette CF Ake HK Tam SW Chang TA Louis 2003 Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection N Engl J Med 348 702-710
18. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30:471-477
19. JJ Monsuez B Gallet L Escaut F Vayre JC Charniot M Pulik M Merad C Minozzi M Slama S Weber D Vittecoq 2000 Clinical outcome after coronary events in patients treated with HIV-protease inhibitors Eur Heart J 21 2079-2080
20. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group 2003 Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 349 1993-2003
21. N Friis-Moller R Weber P Reiss R Thiebaut O Kirk A d'Arminio Monforte C Pradier L Morfeldt S Mateu M Law W El-Sadr S De Wit CA Sabin AN Phillips JD Lundgren 2003 Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study AIDS 17 1179-1193
22. M Law N Friis-Moller R Weber P Reiss R Thiebaut O Kirk A d'Arminio Monforte C Pradier L Morfeldt G Calvo W El-Sadr S De Wit CA Sabin JD Lundgren 2003 Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study HIV Med 4 1-10
23. JA Ambrose RB Gould DC Kurian MC DeVoe NB Pearlstein JT Coppola FP Siegal 2003 Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection Am J Cardiol 92 301-303
24. PY Hsue K Giri S Erickson JS MacGregor N Younes A Shergill DD Waters 2004 Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection Circulation 109 316-319
25. J Miller D Brown J Amin J Kent-Hughes M Law J Kaldor DA Cooper A Carr 2002 A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia AIDS 16 2195-2200
26. A Carr J Hudson J Chuah S Malla M Law J Hoy N Doong M French D Smith DA Cooper 2001 HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study AIDS 15 1811-1822
27. E Martinez JA Arnaiz D Podzamczer D Dalmau E Ribera P Domingo H Knobel M Riera E Pedrol L Force JM Llibre F Segura C Richart C Cortes M Javaloyas M Aranda A Cruceta E de Lazzari JM Gatell 2003 Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection N Engl J Med 349 1036-1046
28. A Carr C Workman DE Smith J Hoy J Hudson N Doong A Martin J Amin J Freund M Law DA Cooper 2002 Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial JAMA 288 207-215